Module 2: Nonclinical Development of AAV-Based Gene Therapy for Spinal Muscular Atrophy
Recorded On: 03/21/2024
Nonclinical Development of Onasemnogene Abeparvovec: Challenges and Translational Clinical Experience. The use of gene therapies as a modality to treat rare monogenic diseases continues to increase as they represent a novel approach to treat, and potentially cure, many of these conditions, including rare CNS diseases. Most of these therapies have employed viral vectors as vehicles for delivering therapeutic genes. Recombinant adeno-associated virus (rAAV)-based vectors are frequently used based on their characteristics of being nonpathogenic and replication-deficient and have a transduction profile that results in stable and prolonged transgene expression in nondividing target cells. OAV101 (onasemnogene abeparvovec) is an rAAV-based gene therapy indicated for the treatment of patients with spinal muscular atrophy (SMA) with biallelic mutations in the survival motor neuron 1 (SMN1) gene. First approved by the FDA in May 2019, OAV101(currently marketed as Zolgensma®) has demonstrated substantial clinical efficacy and relative safety in SMA patients following a single IV dose. To ensure that the benefits of OAV101 can be accessible to a significant segment of the SMA patient pool, intrathecal (IT) OAV101 is currently being developed for late-onset SMA patients aged 2 to 18 years. This talk will focus on the nonclinical program developed to support the initiation of clinical trials following IV infusion or IT injection of OAV101. In addition to the proof-of-concept efficacy studies in SMNΔ7 mice and an induced porcine model of SMA, a toxicology program consisting of single-dose integrated toxicity and biodistribution, tolerability, and investigative studies in neonatal mice and juvenile cynomolgus monkeys supported the clinical administration of OAV101. Potential safety risks such as hepatotoxicity, cardiotoxicity, DRG toxicity, immunogenicity, insertional mutagenesis, and tumorigenicity based on OAV101 nonclinical studies as well as literature on other AAV-based gene therapies will be discussed with an emphasis on DRG toxicity and efforts made to better understand the pathogenesis. Operational challenges for nonclinical studies, as well as the translation of nonclinical findings in the clinical setting, will also be addressed, including measures for clinical trial monitoring.
Francis Tukov, PhD, DVM, DABT
Director of Preclinical Safety Assessment
Novartis Pharmaceuticals Corporation
Dr. Francis Tukov is an experienced board-certified toxicologist with several years of experience in preclinical drug development spanning several therapeutic areas, including Gene Therapy. Since 2019, Dr. Tukov has been leading all Preclinical safety efforts supporting the development of IV onasemnogene abeparvovec (Zolgensma®), the first replacement gene therapy product for the treatment of spinal muscular atrophy. Dr. Tukov continues to lead the preclinical safety activities related to Zolgensma post-marketing and the development of Intrathecal (IT) onasemnogene abeparvovec and other gene therapy-related projects at Novartis. Dr. Tukov is currently a Director of Preclinical Safety Assessment in Novartis Institutes for Biomedical Research (NIBR). He has prior experience as a Study Director/Study Monitor for nonclinical toxicology studies in major disease areas. Francis received a DVM degree in 1995 and obtained a PhD in Pharmacology/Toxicology in 2003.